XBiotech: Up on plans to develop drug for combined COVID-19, flu infections

XBiotech

21/09/2020 14:04

** Shares of drug developer  XBIT.O  rise 3.9% to $21.99
premarket, among handful of components in Nasdaq biotech index
 .NBI  trading higher before the bell 
    ** Co says it will develop antibody therapy to treat illness
caused by combined infections with influenza and new coronavirus
 urn:newsml:reuters.com:*:nGNEbPJGml
    ** XBIT is separately developing antibody therapy for
COVID-19  urn:newsml:reuters.com:*:nXXN2CJ004
    ** Stock up 13.4% YTD 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))